Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2833321 | 0.86 | SMN1; SMN2 (0.50) | MAPTLMNAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2828038 | 0.84 | LMNA (0.45) | MAPTLMNAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2830962 | 0.83 | POLB (0.50) | MAPTLMNAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2827969 | 0.83 | MAPT (0.46) | MAPTLMNAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2828032 | 0.83 | GLA (0.46) | MAPTLMNAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2829858 | 0.82 | GAA (0.46) | MAPTLMNAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2830427 | 0.80 | TSHR (0.50) | MAPTLMNAALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL3262775 | 0.79 | TSHR (0.49) | MAPTLMNAALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL2826926 | 0.78 | TSHR (0.50) | MAPTLMNAALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL2825100 | 0.78 | NPSR1 (0.49) | MAPTLMNAALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168578-A2 | 2-Amido-Thiazole-Based Compounds Exhibiting ATP-Utilizing Enzyme Inhibitory Activity, and Compositions, and Uses Thereof | Genentech, Inc. (US) | 2010-03-31 | — | — | EP | claimed |
| US-20090048313-A1 | 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | GENENTECH, INC. (US) | 2009-02-19 | — | — | US | claimed |
| US-7410988-B2 | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | GENENTECH, INC. (US) | 2008-08-12 | — | — | US | claimed |
| EP-2620150-A2 | 2-Amido Thiazole Based Inhibitors of ATP-Utilizing Enyzmes | Genentech, Inc. (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2168578-A2 | 2-Amido-Thiazole-Based Compounds Exhibiting ATP-Utilizing Enzyme Inhibitory Activity, and Compositions, and Uses Thereof | Genentech, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048313-A1 | 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | ATP5ME, ATP5MG, ATP5MK | MAPT 3561/4885LMNA 4104/4885ALDH1A1 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.